BeiGene Ltd. ADR (B1ME34)

Overview

BeiGene, Ltd. is a globally operating entity dedicated to the development and commercialization of oncology medicines. Founded in 2010 and headquartered in Grand Cayman, the Cayman Islands, BeiGene operates through its subsidiaries to bring innovative cancer treatments to patients worldwide. The company has an extensive portfolio of products aimed at treating various forms of cancer, ranging from blood cancers to solid tumors. BeiGene’s approach to cancer treatment combines a robust development pipeline with strategic collaborations with key industry players such as Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., and several others, aiming to accelerate the development and accessibility of oncology medicines.

Products and Services

• BRUKINSA - A therapy designed to target blood cancers through precision medicine methodologies.
• TEVIMBRA - Offers treatment options for both solid tumor and blood cancer patients, reflecting BeiGene's diverse oncology portfolio.
• PARTRUVIX - Developed for the management of various solid tumor malignancies, showcasing the company's commitment to expanding cancer care solutions.
• XGEVA - Aimed at treating bone metastases from solid tumors and multiple myeloma, plus giant cell tumor of bone, highlighting the company's focus on providing solutions for cancer-related complications.
• BLINCYTO - An acute lymphoblastic leukemia treatment, underlining BeiGene’s dedication to addressing less common but highly aggressive cancer types.
• KYPROLIS - Provides a treatment pathway for R/R multiple myeloma, emphasizing the company's involvement in addressing difficult-to-treat cancers.
• REVLIMID - Focuses on the treatment of multiple myeloma, aligning with BeiGene’s mission to offer diverse therapeutic options.
• VIDAZA - Addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia, showcasing the company’s attention to a wide array of blood disorders.
• SYLVANT - Treats idiopathic multicentric Castleman disease, demonstrating BeiGene's commitment to rare oncological conditions.
• QARZIBA - Used for treating neuroblastoma, indicating the company's focus on pediatric cancers.
• POBEVCY - Provides options for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC), reflecting the company's investment in major cancer types with significant patient populations.
• BAITUOWEI - Designed to treat breast and prostate cancers, highlighting BeiGene's role in tackling some of the most common cancer types.
• TAFINLAR and MEKINIST - These products are tailored for the treatment of NSCLC and melanoma, showcasing BeiGene's investment in targeted cancer therapies.
• VOTRIENT - Focuses on advanced renal cell carcinoma, contributing to the treatment landscape of kidney cancer.
• AFINITOR - Offers solutions for advanced renal cell carcinoma, NET, SEGA, & breast cancers, highlighting the company's broad approach to oncology.
• ZYKADIA - Specifically treats ALK+ NSCLC, indicating the company’s focus on genomic-driven cancer care.

In addition to these marketed products, BeiGene is actively developing a range of inhibitors and antibodies, including Sonrotoclax (BGB-11417), BGB-10188, and Zanidatamab, aimed at providing innovative solutions for cancer patients. This robust development pipeline demonstrates BeiGene’s commitment to advancing cancer treatment and improving patient outcomes.